Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants

References

• Group A-TL-CS. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2033130.
   Google Scholar
• Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori S-I, Sakai-Tagawa Y, Iwatsuki-Horimoto K, et al. Transmission of SARS-CoV-2 in domestic cats. N Engl J Med. 2020;383:1–10. doi:https://doi.org/10.1056/NEJMc2013400.
   PubMedGoogle Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Joseph Im J, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2035002.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:https://doi.org/10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368:945–46. doi:https://doi.org/10.1126/science.abb8923.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi:https://doi.org/10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27. doi:https://doi.org/10.1038/s41586-020-2798-3.
   PubMed Web of Science ®Google Scholar
• Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, Van Buskirk C, Grossman BJ, Joyner M, Henderson JP, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757–65. doi:https://doi.org/10.1172/JCI138745.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–69. doi:https://doi.org/10.1038/s41564-020-0688-y.
   PubMed Web of Science ®Google Scholar
• Liu Z, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, B A, Alford B, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477–488.e4. doi:https://doi.org/10.1016/j.chom.2021.01.014.
   PubMed Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann -H-H, Michailidis E, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9. doi:https://doi.org/10.7554/eLife.61312.
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–18. doi:https://doi.org/10.1126/science.abd0831.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Gilchuk P,  Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, et al. Complete mapping of mutations to the SARS-CoV-2 Spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2020. doi:https://doi.org/10.1016/j.chom.2020.11.007.
   Google Scholar
• Greaney AJ, Katharine ANL, Crawford HD, Starr TN, Malone KD, Chu HY, Bloom JD. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. bioRxiv. 2021. doi:https://doi.org/10.1101/2020.12.31.425021.
   Google Scholar
• Rees-Spear C, Griffith SA, Heaney J, Aldon Y, Snitselaar JL, Thomas P, Graham C, Seow J, Lee N, Rosa A, et al. The impact of Spike mutations on SARS-CoV-2 neutralization. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.01.15.426849.
   Google Scholar
• Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH, Leist SR, Schäfer A, Nakajima N, Takahashi K, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370:1464–68. doi:https://doi.org/10.1126/science.abe8499.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020. doi:https://doi.org/10.1101/2020.12.21.20248640.
   Google Scholar
• Rambaut AEA. Preliminary genomic characterisation of an emergent SARSCoV-2 lineage in the UK defined by a novel set of spike mutations; 2020 [accessed 2020 Dec]. https://virological.org/t/preliminarygenomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-ofspike-mutations/563.
   Google Scholar
• Naveca FEA. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein; 2021 [accessed 2021 Jan 11]. https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585.
   Google Scholar
• Wang. P, Iketani. S, Luo. Y, Guo. Y, Wang. M, Yu. J, Zhang. B, Kwong PD, Graham BS, Mascola JR, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.01.25.428137.
   Google Scholar
• Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE, de Oliveira T, Vermeulen M, van der Berg K.SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–625. doi:https://doi.org/10.1101/2021.01.18.427166.
   Google Scholar
• Wang Z, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616–622.
   Google Scholar
• Kuroiwa Y, Kasinathan P, Sathiyaseelan T, Jiao J-A, Matsushita H, Sathiyaseelan J, Wu H, Mellquist J, Hammitt M, Koster J, et al. Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol. 2009;27(2):173–81. doi:https://doi.org/10.1038/nbt.1521.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Sano A, Wu H, Jiao J-A, Kasinathan P, Sullivan EJ, Wang Z, Kuroiwa Y. Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. PLoS One. 2014;9:e90383. doi:https://doi.org/10.1371/journal.pone.0090383.
   PubMedGoogle Scholar
• Matsushita H, Sano A, Wu H, Wang Z, Jiao J-A, Kasinathan P, Sullivan EJ, Kuroiwa Y. Species-specific chromosome engineering greatly improves fully human polyclonal antibody production profile in cattle. PLoS One. 2015;10:e0130699. doi:https://doi.org/10.1371/journal.pone.0130699.
   PubMedGoogle Scholar
• Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN, Oberlander N, Byrum R, Ragland D, et al. Fully human immunoglobulin G from transchromosomic bovines treats nonhuman primates infected with ebola virus makona isolate. J Infect Dis. 2018;218(suppl_5):S636–S648. doi:https://doi.org/10.1093/infdis/jiy377.
   PubMedGoogle Scholar
• Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao J-A, Matsushita H, Liu Y, Postnikova EN, Ork BL, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016;8(326):326ra321. doi:https://doi.org/10.1126/scitranslmed.aaf1061.
   Web of Science ®Google Scholar
• Perley CC, Hua Wu RLB, Bausch C, Karmali PP, Vega JB, Cohen MV, Somerville B, Kwilas SA, Principe LM, Padmanabh Chivukula JS, et al. Anti-HFRS human igg produced in transchromosomic bovines has potent hantavirus neutralizing activity and is protective in animal models. Front Microbiol. 2020:11. doi:https://doi.org/10.3389/fmicb.2020.00832.
   Google Scholar
• Gardner CL, Sun C, Luke T, Raviprakash K, Wu H, Jiao J-A, Sullivan E, Reed DS, Ryman KD, Klimstra WB, et al. Antibody preparations from human transchromosomic cows exhibit prophylactic and therapeutic efficacy against Venezuelan equine encephalitis virus. J Virol. 2017;91. doi:https://doi.org/10.1128/JVI.00226-17.
   Google Scholar
• Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao J-A, Sullivan E, Luke T, Davey RT. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018;18:410–18. doi:https://doi.org/10.1016/S1473-3099(18)30002-1.
   PubMed Web of Science ®Google Scholar
• Silver JN, Ashbaugh CD, Miles JJ, Wu H, Marecki GT, Hwang JK, Jiao J-A, Abrams M, Sullivan EJ, Wesemann DR, et al. Deployment of transchromosomal bovine for personalized antimicrobial therapy. Clin Infect Dis. 2018;66:1116–19. doi:https://doi.org/10.1093/cid/cix977.
   PubMedGoogle Scholar
• Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei -Y-Y, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–69. doi:https://doi.org/10.1038/s41586-020-2008-3.
   PubMed Web of Science ®Google Scholar
• Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet L-M, Zeng Q, Tahan S, Droit L, et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe. 2020;28:475–485 e475. doi:https://doi.org/10.1016/j.chom.2020.06.021.
   PubMed Web of Science ®Google Scholar
• Alsoussi WB, Turner JS, Case JB, Zhao H, Schmitz AJ, Zhou JQ, Chen RE, Lei T, Rizk AA, McIntire KM, et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. J Immunol. 2020;205:915–22. doi:https://doi.org/10.4049/jimmunol.2000583.
   PubMed Web of Science ®Google Scholar
• Guthe S, Kapinos L, Möglich A, Meier S, Grzesiek S, Kiefhaber T. Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin. J Mol Biol. 2004;337:905–15. doi:https://doi.org/10.1016/j.jmb.2004.02.020.
   PubMed Web of Science ®Google Scholar
• Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, Ballantyne J, Wu H, Jiao J-A, Matsushita H, et al. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med. 2014;6(264):264ra162. doi:https://doi.org/10.1126/scitranslmed.3010082.
   PubMed Web of Science ®Google Scholar
• Klimstra WB, Nambulli T-LN, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, et al. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients. J Gen Virol. 2020;101(11):1156–69. doi:https://doi.org/10.1099/jgv.0.001481.
   PubMedGoogle Scholar
• Gu H, Chen Q, Yang G, He L, Fan H, Deng Y-Q, Wang Y, Teng Y, Zhao Z, Cui Y, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369:1603–07. doi:https://doi.org/10.1126/science.abc4730.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, et al. The impact of mutations in SARS-CoV-2 Spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–1294 e1289. doi:https://doi.org/10.1016/j.cell.2020.07.012.
   PubMed Web of Science ®Google Scholar
• Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, Molenaar RJ, Munger E, Molenkam R, van der Spek A, Tolsma P, Rietveld A, Brouwer M, et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2020. doi:https://doi.org/10.1126/science.abe5901.
   Google Scholar
• Dinnon KH 3rd, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL, Hou YJ, Adams LE, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560–66. doi:https://doi.org/10.1038/s41586-020-2708-8.
   PubMed Web of Science ®Google Scholar
• Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020;368:1016–20. doi:https://doi.org/10.1126/science.abb7015.
   PubMed Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184(7):1804–1820; e1816.
   Google Scholar
• Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18:46–61. doi:https://doi.org/10.1038/nri.2017.106.
   PubMed Web of Science ®Google Scholar